TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems of the aging motor system, not muscle alone. The authors propose broader assessment of movement and nerve function, while acknowledging that new tests have not yet been shown to outperform existing screens.
A paper published in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be understood as problems of the broader motor system, not simply as the result of shrinking muscles. The authors say the proposal could change how clinicians assess sarcopenia, but acknowledge that their suggested measures have not yet been shown to improve outcomes or outperform existing screening tools.
The paper, by Lucas B. R. Orssatto and colleagues, questions a gap between how sarcopenia is diagnosed and how it is commonly explained. Diagnostic approaches have shifted toward measures such as grip strength, walking speed and chair stands, which reflect physical function and can predict outcomes better than muscle mass alone, according to the report. Yet sarcopenia is still often described as a disease primarily of muscle.
The authors argue that muscle loss accounts for only a modest share of strength decline in older adults. People with similar muscle mass can have different strength and mobility, while exercise can improve strength and movement without measurable increases in muscle mass. They propose that changes in the brain, spinal cord, nerves and connections between nerves and muscle also affect how effectively the body produces movement.
The researchers suggest clinicians look beyond whether a person can complete a movement. They propose observing how quickly a person rises from a chair, steadiness during sustained effort, hand dexterity and walking while talking. They also recommend closer examination when weakness is asymmetric, develops rapidly or seems out of proportion to muscle loss. The report says sedative and anticholinergic medicines can blunt motor drive, making medication review relevant alongside exercise.
A Broader View of Mobility Decline
The proposal matters because weakness and impaired mobility can affect falls, disability and independence. In Australia, the report says, falls remain a leading cause of injury-related hospitalization and death. It cites 253,800 fall-related hospitalizations in 2024–25; in the preceding year, 6,722 Australians died after falls, and fall injuries were estimated to cost the health system $5.4 billion.
If the motor-system explanation is supported by further evidence, it could shift research and care away from approaches focused mainly on increasing muscle mass. The authors argue that understanding whether an individual’s difficulty stems from muscle, nerve function or other parts of movement control may help guide more targeted assessment and interventions. That is a proposed direction, not a demonstrated clinical benefit: the paper does not establish that the suggested approach prevents falls or preserves independence.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Function
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. Medical Xpress reports that it affects up to 29% of older adults living in the community, with higher rates in hospitals and residential elder care, and among people with frailty or multiple health conditions.
Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm for screening, assessing and managing poor muscle health in primary care. The new paper takes up a related question: if clinical assessments increasingly measure strength and performance rather than muscle size, should the underlying account of sarcopenia also change? Its authors propose a five-point agenda for international groups that set diagnostic criteria, including validation of practical tests and trials that measure nerve as well as muscle function.
“Nobody has yet shown that these measures beat existing screens, either on outcomes or on cost.”
— The paper’s authors, as reported by Medical Xpress
Tests and Benefits Still Unproven
The report does not provide evidence that the proposed motor-system measures improve patient outcomes, reduce falls or offer better value than current screening. The authors explicitly say those comparisons have not been demonstrated. It is also unclear which practical tests would be suitable for routine primary care, how they should be interpreted, or whether clinicians can access the neuromuscular expertise needed to assess results.
The paper presents a framework and research agenda, not a new diagnostic standard or treatment recommendation. The report does not specify when international working groups might review diagnostic criteria or what evidence would be required to change them.
Validation Before Guideline Changes
The authors call for research to validate practical, usable assessments, compare them with current screening methods on outcomes and costs, and test interventions that address nerve and muscle function. They also want guidelines to support a staged approach to assessment.
For now, the proposed reframing does not replace existing diagnostic criteria. The next milestone is evidence showing whether broader motor-system testing helps clinicians identify causes of weakness more accurately and whether that information leads to better care. Until then, the authors’ recommendations remain a call for further study.
Key Questions
What does the paper mean by the aging motor system?
It refers to the structures involved in producing movement, including the brain, spinal cord, nerves and muscles, and the connections among them. The authors argue that aging can affect movement control as well as muscle tissue.
Does the paper say muscle loss is irrelevant?
No. The authors do not dismiss muscle loss. They argue it explains only a modest share of strength decline and that muscle mass alone cannot account for differences in strength and mobility among older adults.
Are clinicians being asked to change diagnosis now?
No change to diagnostic criteria is reported. The paper proposes a research and assessment agenda; its suggested measures have not yet been shown to outperform existing screens.
What tests or observations do the authors suggest?
They suggest observing how quickly someone rises from a chair, steadiness during sustained effort, hand dexterity and walking while talking, alongside measures such as grip strength and gait speed. These suggestions still require validation for routine care.
Source: medicalxpress.com
